Page 149 - 2019_07 resto del Mondo-web

Targeting BCL2 with venetoclax for DH-DPL
patients with relapsed or refractory non- Hodgkin lymphoma. J Clin Oncol. 2017;35(8): 826-833.
26. Pérez-Galán P, Roué G, López-Guerra M, et al. BCL-2 phosphorylation modulates sensi- tivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic inter- action with bortezomib in chronic lympho- cytic leukemia cells. Leukemia. 2008;22(9): 712-1720.
27. Dai H, Ding H, Meng XW, Lee S-H, Schneider PA, Kaufmann SH. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 2013;73(23): 6998-7008.
28. Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132-1144.
29. Isobe Y, Sugimoto K, Matsuura I, Takada K, Oshimi K. Epstein-Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis. Br J Cancer. 2008;99(11):1816-1822.
30. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
31. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical sta- tistics. Bone Marrow Transplant. 2013;48(3): 452-458.
32. Leverson JD, Phillips DC, Mitten MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer thera- py. Sci Transl Med. 2015;7(279):279ra40.
33. Ruvolo VR, Kurinna SM, Karanjeet KB, et al. PKR regulates B56a-mediated BCL2 phos- phatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem. 2008;283(51):35474-35485.
34. Low ICC, Loh T, Huang Y, Virshup DM, Pervaiz S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity. Blood. 2014;124(14):2223-2234.
35. Fujise K, Zhang D, Liu J, Yeh ETH. Regulation of apoptosis and cell cycle pro-
gression by MCL1. Differential role of pro- liferating cell nuclear antigen. J Biol Chem. 2000;275(50):39458-39465.
36. Wenzel SS, Grau M, Mavis C, et al. MCL1 is deregulated in subgroups of diffuse large B- cell lymphoma. Leukemia. 2013;27(6):1381- 1390.
37. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeu- tic strategy to target c-Myc. Cell. 2011;146(6):904-917.
38. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981-2989.
39. Nifoussi SK, Ratcliffe NR, Ornstein DL, Kasof G, Strack S, Craig RW. Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr- 163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lym- phoma cells. J Biol Chem. 2014;289(32): 21950-21959.
40. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
haematologica | 2019; 104(7)
1427